OmniInsight™ Comprehensive Genomic Risk Evaluation (Advanced PRS + Monogenic)

OmniInsight™ Comprehensive Genomic Risk Evaluation (Advanced PRS + Monogenic)

$2,500.00

A single saliva test provides a comprehensive, clinically driven panel covering major
cancers, cardiovascular and metabolic diseases, as well as neurological, autoimmune,
and other chronic conditions across the lifespan. By integrating polygenic risk scores
(PRS) and the American College of Medical Genetics and Genomics-recommended
actionable genes with an expanded set of clinically relevant genes—spanning 81 gene
mentions across panels (55 unique genes), Avigena deliver a powerful and clinically
meaningful risk assessment, empowering you and your clinician to act early and prevent
disease.

Results in 4–8 weeks. Free Genetic Counseling. 
Get a personalized report and a free virtual session to help you understand your risk
and take preventive steps.
*Price includes Comprehensive Genomic Risk Test: report, counseling, and prevention roadmap

Code: OI-COMP-02 Category:

One test. Multiple layers of protection.

Cardiovascular, cancer, metabolic diseases, autoimmune, neurological and other chronic conditions PRS and Monogenic Genetic Test

Validated across diverse ancestry and tailored to the Arab and Middle Eastern population
With Avigena, a single saliva test provides both a comprehensive panel covering major cancers, cardiovascular and metabolic diseases across lifespan; empowering you and your clinician to protect your health today and prevent disease tomorrow.

Avigena offers a unique genetic test that integrates:

1- Polygenic Risk Scores (PRS) with a validated analysis across common diseases, including cancers, cardiovascular and metabolic diseases, as well as neurological, autoimmune, and other chronic conditions. Diseases include cancers such as : Breast cancer, Prostate cancer, Ovarian cancer, Melanoma, Colorectal cancer. Cardiovascular and metabolic diseases including: Coronary artery disease (CAD), Atrial Fibrillation, Stroke, Type 2 Diabetes, Hypertension, High body mass index (BMI), High triglycerides, Hypo-HDL cholesterolemia, Polygenic hypercholesterolemia, High lipoprotein (a). In addition to other diseases : Alzheimer’s disease ;Inflammatory Bowel Disease (IBD); Early menopause; Osteoporosis; and Celiac disease

2- Expanded set of clinically relevant genes—spanning 81 gene mentions across panels (55 unique genes), Focuses on reporting pathogenic and likely pathogenic variants in genes linked to medically actionable conditions.

Why This Matters

  • PRS adds breadth: capturing the cumulative impact of millions of small genetic variants on common diseases risk.
  • Monogenic findings add precision: identifying rare, high-impact mutations with strong clinical guidelines for prevention or treatment.
  • ACMG coverage extends to the heart, cancer, metabolic, autoimmune and neurological diseases: ensuring patients are also informed of hidden, actionable risks for preventable diseases.
Know More

What you receive

  • A personalized report covering both PRS and monogenic risks.
  • Clear prevention strategies tailored to your results.
  • A virtual genetic counseling session to help you understand your report and discuss next steps with your care team.
  • Lab quality assurance: Testing performed in collaboration with the Laboratory for Molecular Medicine at Mass General Brigham Personalized Medicine, with results in 4–8 weeks.

Who Should Consider This Test

Adults seeking preventive cardiovascular insights.

Individuals with a family history of heart disease or cancer.

Those who developed the disease without traditional risk factors.

Anyone looking for advanced, proactive health management through genomics.

Results in 4–8 weeks. Free Genetic Counseling. 

Get a personalized report and a free virtual session to help you understand your risk and take preventive steps.

* Price includes Comprehensive Genomic Risk Test: report, counseling, and prevention roadmap.

[email protected]